Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

BIOMARKER:

RB1 expression

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related biomarkers:

‹

EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRCA1 mutation + RB1 deletion (1)

BRCA2 mutation + RB1 deletion (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

HR positive + RB1 mutation (1)

MET amplification + RB1 wild-type (1)

RB1 mutation + HR positive (1)

RB1 mutation + PD-L1 expression (1)

TMB-H + RB1 mutation + PD-L1 underexpression (1)

TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)

TMB-L + RB1 mutation (1)

TP53 deletion + RB1 deletion + CTSK expression (1)

EGFR exon 19 deletion + TP53 mutation + RB1 mutation (2)

BRAF V600E + CDKN2A deletion + RB1 expression (1)

BRAF V600K + CDKN2A deletion + RB1 expression (1)

BRCA1 mutation + RB1 deletion (1)

BRCA2 mutation + RB1 deletion (1)

EGFR C797S + KRAS amplification + RB1 deletion (1)

EGFR L858R + KRAS amplification + RB1 deletion (1)

EGFR T790M + KRAS amplification + RB1 deletion (1)

HR positive + RB1 mutation (1)

MET amplification + RB1 wild-type (1)

RB1 mutation + HR positive (1)

RB1 mutation + PD-L1 expression (1)

TMB-H + RB1 mutation + PD-L1 underexpression (1)

TMB-H + RB1 L518fs*6 + ERCC4 R799W + TP53 C124* (1)

TMB-L + RB1 mutation (1)

TP53 deletion + RB1 deletion + CTSK expression (1)

›

RB1 expression	Glioblastoma	RB1 expression	Glioblastoma	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3	palbociclib Resistant: C3 – Early Trials palbociclib Resistant : C3
RB1 expression	Liposarcoma	RB1 expression	Liposarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
RB1 expression	Soft Tissue Sarcoma	RB1 expression	Soft Tissue Sarcoma	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3	palbociclib Sensitive: C3 – Early Trials palbociclib Sensitive : C3
RB1 expression	Breast Cancer	RB1 expression	Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3	CDK4 inhibitor + CDK6 inhibitor Sensitive: C3 – Early Trials CDK4 inhibitor + CDK6 inhibitor Sensitive : C3
RB1 expression	Prostate Cancer	RB1 expression	Prostate Cancer	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D	palbociclib Sensitive: D – Preclinical palbociclib Sensitive : D
RB1 expression	Hepatocellular Cancer	RB1 expression	Hepatocellular Cancer	lenvatinib + ribociclib Sensitive: D – Preclinical lenvatinib + ribociclib Sensitive : D	lenvatinib + ribociclib Sensitive: D – Preclinical lenvatinib + ribociclib Sensitive : D
RB1 expression	Hepatocellular Cancer	RB1 expression	Hepatocellular Cancer	lenvatinib + abemaciclib Sensitive: D – Preclinical lenvatinib + abemaciclib Sensitive : D	lenvatinib + abemaciclib Sensitive: D – Preclinical lenvatinib + abemaciclib Sensitive : D